J Cancer Res Ther [JOURNAL]
Sun
200 papers
Assessment of response to total neoadjuvant therapy in carcinoma rectum: A real-world prospective observational study from eastern India.
Mukherjee P, Barik SK, Majumdar SKD … +22 more , Das DK, Ramasubbu MK, Ahmed SS, Muduly DK, Sasmal PK, Mishra TS, Pattnaik B, Dutta T, Gupta S, Dhar SS, Pattanaik A, Mahapatra BR, Badajena A, Mishra M, Kanungo S, Haroon KMN, Devi UP, Muraleedharan A, Mahajan A, Abdulla SS, Sarkar A, Parida DK
J Cancer Res Ther · 2025 Jul · PMID 41004293 · Publisher ↗
BACKGROUND: Preoperative chemoradiotherapy and subsequent surgery is the standard of care for locally advanced rectal cancer. This has resulted in good local control, but without a significant survival benefit. Multiple...
BACKGROUND: Preoperative chemoradiotherapy and subsequent surgery is the standard of care for locally advanced rectal cancer. This has resulted in good local control, but without a significant survival benefit. Multiple randomised trials have utilised total neoadjuvant therapy (TNT) to improve survival outcomes. However, clinical experience in India is limited. METHODS: Patients with cT3/4 or N + rectal adenocarcinoma with ECOG 0-1 were included. Treatment course comprised Short-course radiotherapy (25 Gy in 5 fractions over 1 week), followed by 6 cycles of chemotherapy (Inj. oxaliplatin 130 mg/m2 on D1 and Tab capecitabine 1000 mg/m2 BID from D1-14, q21 days). Following the completion of neoadjuvant treatment, patients were assessed for surgery. Surgery involved Total Mesorectal Excision. RESULTS: 32 patients were enrolled. Males comprised 66% of the population, and the median age was 42 years. 75% of patients had distal rectal tumours. 18.8% were signet ring cell carcinoma (SRC). 43.8% of patients had mesorectal fascia involvement and lateral lymph nodes (LLN) were present in 28% patients. All patients completed the full course of TNT. 84.4% patients underwent definitive surgery. Pathological complete response was reported in 37% patients, with R0 resection in 96%. Sphincter preservation could be achieved in 29.2% of distal tumours. The incidence of acute grade 3 or higher adverse events was 40.6%, the most common being diarrhoea (15.6%), followed by anaemia (9.4%). Post-operative complications were seen in 22.2% of patients, the most frequent being delayed wound healing. The incidence of Clavien-Dindo grade IV complications was 3.7%. At a median follow-up of 2 years, OS and PFS were 75% and 59.4%, respectively. Absence of LLN and non-SRC histology was associated with significantly higher PFS and OS. CONCLUSION: The TNT protocol we followed was well tolerated in our patient population. Excellent tumour and nodal regression rates were seen. It can be considered a viable alternative to preoperative conventional chemoradiation, particularly in a resource-limited setting. However, this treatment strategy was not optimal for patients with high-risk features such as the presence of LLNs and SRC histology.
Phase-II randomized study of carboplatin plus capecitabine versus 3-weekly cisplatin in locally advanced head-and-neck cancer patients undergoing concurrent chemoradiation (CARCAP-HN).
Mohanty S, Samal K, Gangadaran SGD … +3 more , Kannan J, Ramkumar B, Saravanan S
J Cancer Res Ther · 2025 Jul · PMID 41004292 · Publisher ↗
BACKGROUND: A substantial proportion of locally advanced head-and-neck squamous cell cancer (LAHNSCC) patients remain ineligible for cisplatin-based chemoradiation due to its frequent toxicities. The study was conducted...
BACKGROUND: A substantial proportion of locally advanced head-and-neck squamous cell cancer (LAHNSCC) patients remain ineligible for cisplatin-based chemoradiation due to its frequent toxicities. The study was conducted to compare carboplatin plus capecitabine versus 3-weekly cisplatin in LAHNSCC patients undergoing definitive chemoradiation. MATERIALS AND METHODS: In this phase II randomized trial, stage 3 or 4 laryngeal or pharyngeal cancer patients received radiation dose of 66-70 gray in 33-35 fractions and were randomized (1:1) to weekly carboplatin (AUC 1.5) plus capecitabine 850 mg/m2/day on the radiation days versus 3-weekly cisplatin (50 mg/m2 on day 1 and day 2). The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints included grade ≥ 3 treatment toxicities and treatment interruption rate (TIR). The study is registered with CTRI number CTRI/2020/11/029290. RESULTS: A total of 81 patients were studied, 40 in the experimental and 41 in the control arm. At a median follow-up of 12.5 months, the median PFS was 14 months versus 12.5 months (P = 0.715). The ORR was 97.5% versus 94.7%, whereas the complete response rate was 57.5% versus 42.1% in the experimental and control arm, respectively (P = 0.449). Significantly lower grade ≥3 toxicity was observed in the experimental arm, i.e., oral mucositis (P = 0.000), vomiting (P = 0.000), nephropathy (P = 0.014), dyselectrolytemia (P = 0.013), fatigue (P = 0.006), anorexia (P = 0.004). The TIR was significantly lower in the experimental arm (P = 0.000). CONCLUSIONS: Carboplatin plus capecitabine-based chemoradiation shows similar efficacy with lesser toxicity compared to 3-weekly cisplatin-based chemoradiation in LAHNSCC.
Scrotal metastasis of colorectal carcinoma with unusual presentation and late recurrences: A study from a tertiary care oncology center in India.
Bilala D, Yadav S, Ankathi SK … +6 more , Kumar R, Deshpande G, Bal M, Deodhar K, Menon S, Ramadwar M
J Cancer Res Ther · 2025 Jul · PMID 41004291 · Publisher ↗
BACKGROUND: Colorectal carcinoma (CRC) is a common malignancy, frequently metastasizing to the liver, lungs, and regional lymph nodes. However, metastasis to the scrotum is exceedingly rare, with few cases reported in th...
BACKGROUND: Colorectal carcinoma (CRC) is a common malignancy, frequently metastasizing to the liver, lungs, and regional lymph nodes. However, metastasis to the scrotum is exceedingly rare, with few cases reported in the literature. In this study, we present a series of five cases of CRC metastasizing to the scrotum, emphasizing their unusual clinical presentation and late recurrences. METHODS: We did a retrospective review of 7 years from 2015 to 2022 for cases of scrotal metastasis in cases of CRC. RESULTS: The mean age in our study was 38 years (22-61 years) and the median time interval between the primary diagnosis and scrotal metastasis was 31.6 months (0-104 months). The cases include scrotal swelling initially misdiagnosed as a hydrocele (case 1), nonhealing cutaneous ulcers (cases 3 and 5), a scrotal skin papilloma (case 4), and a cutaneous nodule (case 2). CONCLUSION: This series of five cases highlights the rarity and diagnostic challenges associated with CRC metastasizing to the scrotum. The extended latency between primary tumor diagnosis and scrotal metastasis, coupled with atypical clinical presentations, underscores the importance of maintaining a high index of suspicion. Clinicians should be vigilant, especially when evaluating patients with a history of CRC, to promptly identify such uncommon metastatic sites.
Clinical outcomes with combination of stereotactic body radiation therapy in patients with hepatocellular carcinoma.
Sahai P, Mall A, Solanky AP … +7 more , Jawahar V, Bharadwaj MS, Jaleel J, Jagya D, Kumar G, Shasthry SM, Yadav HP
J Cancer Res Ther · 2025 Jul · PMID 41004290 · Publisher ↗
PURPOSE: The purpose of the present study was to evaluate outcomes with a combination of stereotactic body radiation therapy (SBRT) for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The present ret...
PURPOSE: The purpose of the present study was to evaluate outcomes with a combination of stereotactic body radiation therapy (SBRT) for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The present retrospective study included 46 patients with 1-3 liver lesions with portal vein tumor thrombosis (PVTT) in 27 treated with definitive, consolidative, or salvage SBRT. The patients had Barcelona Clinic Liver Cancer (BCLC) stage A, B, or C disease (n = 44) with new, residual, progressive, or recurrent lesions with prior liver-directed and/or systemic therapy (n = 37). The median combined maximum diameter of the lesions was 7.48 cm (range, 1.55-16.5 cm). The dose fractionation for SBRT was 24-50 Gy in 5-8 fractions (median = 30 Gy in 6 fractions) with volumetric modulated arc technique on linear accelerator. Systemic treatment with sorafenib, lenvatinib, and/or nivolumab was given in 35 patients. Liver-directed interventional treatment after SBRT was given in 10 patients. Treatment response was evaluated as per mRECIST with or without Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST), and Kaplan-Meier survival analysis was performed. RESULTS: Patient-reported relief in symptoms was observed in 59.4% after SBRT. Of 46, 27 (58.7%) had decreased serum tumor markers with AFP and/or PIVKA-II at 3 months after SBRT with systemic treatment. The median overall survival (OS) was 21.4 months (95% CI: 14.3-28.5 months) after the index cancer diagnosis. The 6-month, 1-year, 2-year, and 3-year OS rates after diagnosis were 84.8%, 60.6%, 44.7%, and 28.2%, respectively. The median OS was 25.3 months versus 10.9 months in patients without versus with PVTT, respectively. Early response at 3-4 months after SBRT with systemic therapy (complete or partial (n = 29) versus stable or progressive (n = 17)) showed an independent association with OS (P ≤ 0.001, hazard ratio (HR) 3.88, 95% CI: 1.94-7.77). The estimated 1-year and 2-year local control rates in all patients were 94.1% and 89.6% after SBRT with systemic therapy. One patient had conversion surgery. Grade 3 hepatic toxicity during SBRT was 10.9%. Liver dysfunction with a Child-Pugh score of 2 or more points within 3 months after SBRT with systemic therapy was noted in 27.3% of patients. Late gastrointestinal toxicity was observed in 1 patient (2.17%). CONCLUSION: The present study suggested that a combination of radiotherapy with other liver-directed and/or systemic treatments is associated with favorable disease control and prolongation of survival in patients with early to advanced-stage HCC.
Prevalence of submandibular gland involvement in oral carcinoma. A retrospective cohort study.
Sreekanth S, Shetty P, Sandeep KM … +4 more , Ray S, Shetty S, Srikant N, Kola N
J Cancer Res Ther · 2025 Jul · PMID 41004289 · Publisher ↗
BACKGROUND: Refining the overall survival of oral cancer patients has gained traction in the treatment of oral cancer by offering a good quality of life. Restoring the anatomy and function of the glands in the oral cavit...
BACKGROUND: Refining the overall survival of oral cancer patients has gained traction in the treatment of oral cancer by offering a good quality of life. Restoring the anatomy and function of the glands in the oral cavity has also been an issue of attention. During every neck dissection, the submandibular gland (SMG) is electively removed as a prophylactic measure. The aim of this study was to evaluate the prevalence of SMG involvement in oral cancer patients and to determine the oncological safety of preserving the SMG during neck dissection in patients with oral cancer. RESEARCH DESIGN AND METHODS: A total of 215 patients with oral cancer who underwent neck dissection and tumor excision between 2007 and 2018 were included in the study. All data were retrieved from patients treated in a single hospital. Data, including demographics, tumor site, degree of differentiation, involvement of the SMG, Grade of differentiation, and treatment regimens, were collected and evaluated. RESULTS: Oral cancer was predominant in males, with an increased preponderance amongst the age group of 55 to 65 years. The tongue was the predominant tumor subsite. Only 6.5% of all cases involved the submandibular gland, with the majority of cases involved the floor of the mouth as the primary tumor location, followed by Tongue. CONCLUSION: The present study revealed that SMG involvement occurs mostly when the primary tumor site is in close proximity to the gland, such as the floor of the mouth and tongue. However, metastasis to the SMG from other primary sites is very rare. Hence, the decision regarding the excision of the SMG in oral cancer patients should be made during surgery through meticulous frozen section instead of routine excision of the gland during neck dissection. We recommend preserving the SMG in patients with oral malignancies with no compromise in oncological clearance and remaining cautious while dealing with primary subsites, such as the floor of the mouth and tongue, that are in close vicinity to the submandibular gland.
The impact of radiation therapy and chemotherapy in locally advanced unresectable nonmetastatic pancreatic cancer patients treated in a tertiary care center.
Alam Z, Pradhan S, Shinghal A … +7 more , Pujari L, Kapoor A, Giridhar P, Kapoor AR, Tanvee, Tripathi M, Mukherji A
J Cancer Res Ther · 2025 Jul · PMID 41004288 · Publisher ↗
BACKGROUND: Locally advanced pancreatic cancer (LAPC) is currently treated with chemotherapy (CT) alone or CT combined with radiation therapy (RT) (CT+RT). There is no robust evidence supporting one over the other. The p...
BACKGROUND: Locally advanced pancreatic cancer (LAPC) is currently treated with chemotherapy (CT) alone or CT combined with radiation therapy (RT) (CT+RT). There is no robust evidence supporting one over the other. The present study compares the two treatment modalities in terms of their survival outcomes and safety profile. METHODS: The retrospective study includes 29 nonmetastatic, unresectable, LAPC patients who were treated with CT+RT (21 patients) or CT alone (8 patients) during November 2019 to September 2023. CT consisted of FOLFIRINOX or Gemcitabine-based regimens. CT+RT patients were treated with conventional (50.4 Gy/28fr) as well as hypofractionated RT dose schedules (39 Gy/13fr, 25 Gy/5fr, and 42 Gy/6fr). The primary endpoint of the study was the median overall survival (OS), and the secondary endpoints were the median progression-free survival (PFS) and acute and late radiation-induced toxicities. RESULTS: At a median follow-up of 24 months, patients of CT+RT group had prolonged survival compared to patients of CT alone group with median OS of 20 months versus 7 months (P = 0.0032) and median PFS of 15 months versus 5 months (P = 0.029). The majority of toxicities in CT+RT group were Grade 1-2 around 79%. However, Grade 3 or more late event was seen only in 1 (5%) patient. CONCLUSION: Incorporating radiation therapy along with CT should be the standard approach for unresectable LAPC patients improving survival with acceptable toxicities.
Hypofractionated radiotherapy in carcinoma breast - A 5-year single institution experience.
Garg P, Goyal N, Priya S … +2 more , Grover R, Singh S
J Cancer Res Ther · 2025 Jul · PMID 41004287 · Publisher ↗
BACKGROUND: Hypofractionated Radiotherapy has replaced Conventional Radiotherapy in Carcinoma Breast. This study aimed to assess locoregional failure, disease-free survival, and overall survival in patients treated over...
BACKGROUND: Hypofractionated Radiotherapy has replaced Conventional Radiotherapy in Carcinoma Breast. This study aimed to assess locoregional failure, disease-free survival, and overall survival in patients treated over 5 years in our institution. MATERIALS AND METHODS: A total of 453 patients with carcinoma of the breast eligible for whole breast radiotherapy were assessed from January 2018 to December 2023. Two-dimensional Radiotherapy was given via Telecobalt or LINAC. Demographic, disease, and treatment-related data were analyzed. RESULTS: Median follow-up was 2.75 years (Range 0.3-5.2 years). Breast-conserving surgery and modified radical mastectomy were done in 21.81% and 78.18% of patients respectively. Neoadjuvant chemotherapy was given in 55.2% of cases. Pathologically, 54.2% of patients had Stage IIB-IIIB and 45.7% had I-IIA.70.84% were given 42 Gy/15 # and the rest of them were given either 41.6 Gy/16 # or 40 Gy/15 #. Percentages of acute skin toxicities Grade I, II, and chronic were observed in 23.11%, 3.97%, and 5.07%, respectively. There were a total of 16 locoregional recurrences and 27 cases of distant metastasis in 5 years. Overall survival and disease-free survival after 5 years were 94.2% and 90.5%, respectively. CONCLUSION: Hypofractionated radiotherapy is a safe and efficacious choice for radical treatment of carcinoma breast patients post-surgery. It provides superlative results in concern to disease-free survival and overall survival with minimal acute and chronic toxicities.
Theranostics and personalized radiopharmaceuticals.
Sushant S, Sharma DN, Saini SK … +3 more , Mrinalini M, Maurya P, Dharmashaktu Y
J Cancer Res Ther · 2025 Jul · PMID 41004286 · Publisher ↗
Theranostics represents a novel approach in modern medicine, merging diagnostic and therapeutic methods into a unified framework tailored to individual patient needs. The current review explores the impact of personalize...
Theranostics represents a novel approach in modern medicine, merging diagnostic and therapeutic methods into a unified framework tailored to individual patient needs. The current review explores the impact of personalized radiopharmaceuticals on the evolution of theranostics, particularly within oncology. The development of these specialized agents has revolutionized the way diseases are detected and treated, offering a more precise method that targets specific molecular features of tumors. By combining the ability to diagnose and treat with the same radiopharmaceutical, theranostics enables a more focused and efficient treatment pathway, minimizing adverse effects while enhancing therapeutic success. Personalized radiopharmaceuticals play a crucial role in this approach, offering the ability to monitor disease activity and therapeutic response in real time, thus providing critical insights for ongoing care. Integrating these advanced techniques into clinical practice is paving the way for more individualized cancer treatment, aligning with the broader goal of precision medicine. As this field advances, theranostics is expected to significantly improve patient outcomes and quality of life, marking a significant leap forward in personalized cancer care.
Radium brachytherapy a predecessor to modern brachytherapy: A historical review from an Indian perspective.
Thayalan K, Ravichandran R
J Cancer Res Ther · 2025 Jul · PMID 41004285 · Publisher ↗
The discovery of X-rays and radium formed the basis of radiation therapy. Radium was the first radioisotope used in medicine in the form of surface mold, intracavitary, and interstitial implants, which is a highly confor...
The discovery of X-rays and radium formed the basis of radiation therapy. Radium was the first radioisotope used in medicine in the form of surface mold, intracavitary, and interstitial implants, which is a highly conformal form of radiation therapy. India was one of the early users of radium, and Colonel Vaughan J.C. used 10 mg of radium at Ranchi. Major V Arthur Ponnaiah, was appointed as a radium safety officer, Barnard Institute of Radiology, Chennai, the first in India. The methods, Sievert integral, Manchester system, and Patterson-Parker rules, along with milligram-hour and millicurie-destroyed per square cm, were used in dosimetry. K Munjunath Rai (Chennai), P. K. Haldar (Agra), J. P. Sinha (Patna), and M.L. Aggarwal (Amritsar) were the pioneers of earlier radium applications in India. Y. Siddique had an exclusive radiation therapy training and was awarded by the Faculty of Radiologists (Present FRCR), London. Tata Memorial Hospital (TMH) established the first Radon plant in India under the physicist Ramaiah Naidu. Due to its long half-life, loss of sources, chances of leakage of radioactive material, and bent needles, radium was withdrawn from hospitals and replaced by a Manual Cs-137 kit, supplied by the Bhabha Atomic Research Centre (BARC). Later, Iridium-192 wires were used for manual interstitial implants, followed by remote after-loading systems. Establishment of the specialty of radiology and taking over radium from the purview of surgeons were a challenge in many hospitals. The journey of radium application was an early milestone of cancer therapy management, which was built over the sacrifices of many Indian surgeons, radiologists, and physicists. This paper reviewed the use of radium, from information collected from the individuals and hospitals who had the opportunity to work with them.
Genomic profiling of head and neck adenoid cystic carcinoma: A systematic review and meta-analysis.
Sharma M, Narwal A, Kamboj M … +3 more , Devi A, Kumar A, Vijayakumar G
J Cancer Res Ther · 2025 Jul · PMID 41004284 · Publisher ↗
Head and neck adenoid cystic carcinoma (ACC) is a common malignancy often associated with an aggressive clinical course and a wide array of gene mutations. This systematic review aimed to determine the prevalence of thes...
Head and neck adenoid cystic carcinoma (ACC) is a common malignancy often associated with an aggressive clinical course and a wide array of gene mutations. This systematic review aimed to determine the prevalence of these mutations and their association with prognosis and recurrence in ACC. A search of the scientific literature was carried out from inception till 31 July 2024 in the electronic databases - PubMed, EMBASE, Scopus, Web of Science, Ovid/MEDLINE, and Science direct following specific eligibility criteria. The methodological quality of the included studies was assessed using the Newcastle-Ottawa tool. 31 studies were included, and numerous genes like MYB, NOTCH, TP53, PIK3CA, ARID1A, KDM6A, RAS, SPEN, and many more were identified and were related to poor prognosis. Identification of different genes using wide NGS panels and combination of molecular techniques becomes necessary as multiple genes might be involved in ACC pathogenesis and subsequent targeted therapies can be designed.
Current state and future of nonsurgical management of metastatic liver tumors.
Sharma N, Nepal A, Sudadi S … +2 more , Kashyap R, Sharma DN
J Cancer Res Ther · 2025 Jul · PMID 41004283 · Publisher ↗
Abstract loading — click title to view on PubMed.
Esophageal pericardial fistula following radiation therapy after placement of an esophageal stent: A case report and literature review.
Xie X, Cong C, Liu P … +3 more , Zhang N, Liu S, Han B
J Cancer Res Ther · 2025 Sep · PMID 40905882 · Publisher ↗
Esophageal pericardial fistula is a rare complication of esophageal cancer. This article reports the first documented case of an esophageal pericardial fistula following radiotherapy in the presence of an esophageal sten...
Esophageal pericardial fistula is a rare complication of esophageal cancer. This article reports the first documented case of an esophageal pericardial fistula following radiotherapy in the presence of an esophageal stent. A 62-year-old man with advanced esophageal and cardiac cancer underwent radiotherapy after esophageal stent placement and subsequently developed an esophageal pericardial fistula. He was admitted to the hospital with symptoms of epigastric pain and breathlessness. A computed tomography scan of the chest revealed an esophageal pericardial fistula, massive pericardial effusion, and pneumopericardium. The esophagogram revealed esophageal extravasation and an enlarged pericardium. On the basis of these findings, the patient was diagnosed with an esophageal pericardial fistula. His symptoms improved after pericardiocentesis with drainage, nasogastric tube feeding, and short-term antibiotic therapy. Unfortunately, he died 1 month after discharge from the hospital due to sudden massive upper gastrointestinal bleeding.
Primary adrenal NK/T lymphoma: A case report of a rare tumor.
Men J, Li J, Fan D … +1 more , Wang J
J Cancer Res Ther · 2025 Sep · PMID 40905881 · Publisher ↗
Natural killer/T-cell lymphoma (NKTCL) is a subtype of non-Hodgkin's lymphoma characterized by rapid progression. It infrequently involves the adrenal glands and exhibits swift advancement. A 52-year-old woman was admitt...
Natural killer/T-cell lymphoma (NKTCL) is a subtype of non-Hodgkin's lymphoma characterized by rapid progression. It infrequently involves the adrenal glands and exhibits swift advancement. A 52-year-old woman was admitted to the hospital with bilateral renal pain. The patient was diagnosed with adrenal NKTCL by puncture biopsy and subsequently underwent a modified SMILE chemotherapy regimen at our institution. During the initial stages of chemotherapy, the patient experienced myelosuppression, which resulted in a severe infection, shock, and eventual death. The SMILE regimen is associated with adverse effects and carries the risk of fatality due to complications related to chemotherapy. Therefore, there is an immediate need for novel chemotherapy regimens that demonstrate efficacy while minimizing adverse effects.
Complete response in a patient with metastatic metaplastic breast cancer treated with immune checkpoint inhibitor and chemotherapy: A case report and a review of the literature.
Chen J, Liu J, Li Y … +9 more , Liu C, Zhang X, Zheng B, Si L, Zhang M, Zhang X, Xu S, Nie W, Wang J
J Cancer Res Ther · 2025 Sep · PMID 40905880 · Publisher ↗
Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer characterized by poor prognosis and lack of treatment guidance. It is notably resistant to conventional chemotherapy. Currently, immunotherapy is becomi...
Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer characterized by poor prognosis and lack of treatment guidance. It is notably resistant to conventional chemotherapy. Currently, immunotherapy is becoming a promising option for multiple tumor types, including triple-negative breast cancer. This report presents a case of triple-negative MpBC that achieved a complete response with a combination of chemotherapy and immune checkpoint inhibitors. We examined the tumor's imaging and histological features, along with the treatment regimen and efficacy. Notably, no major toxicities related to immunotherapy were observed. To our knowledge, this is the first case report demonstrating the effectiveness of lambrolizumab in combination with the GP chemotherapy regimen for treating triple-negative breast cancer in general and specifically metastatic MpBC.
Retrospective study of the characteristics of early gastric cancer with surrounding map-like redness after successful Helicobacter pylori eradication.
Li Y, Wei Y, Yu Y … +1 more , Yin X
J Cancer Res Ther · 2025 Sep · PMID 40905879 · Publisher ↗
BACKGROUND: Map-like redness (MLR) is a high-risk membrane factor for early gastric cancer (EGC) after the successful eradication of Helicobacter pylori (Hp). This study aimed to analyze the clinical, endoscopic, and pat...
BACKGROUND: Map-like redness (MLR) is a high-risk membrane factor for early gastric cancer (EGC) after the successful eradication of Helicobacter pylori (Hp). This study aimed to analyze the clinical, endoscopic, and pathological characteristics of EGC with surrounding MLR after successful Hp eradication and evaluate the effect of endoscopic submucosal dissection (ESD) resection. METHODS: This retrospective study comprised 23 patients with EGC and surrounding MLR after Hp eradication (MLR group) and 135 patients with EGC without a surrounding MLR (non-MLR; NMLR group). The clinical, pathological, and endoscopic characteristics were compared, and the effect of ESD resection was evaluated. RESULTS: A total of 158 patients were enrolled (age range: 41-77 years). The MLR group had a higher proportion of males (P = 0.020) and more severe atrophy (P = 0.003) and intestinal metaplasia (P = 0.007) than the NMLR group. The endoscopic features of the MLR group included localization in the middle part of the stomach (P < 0.001), a red color (P = 0.002), a larger size (P = 0.015), a greater proportion of type IIb tumors (P < 0.001), and unclear lesion borders (P < 0.001) compared to the NMLR group. Differentiated adenocarcinoma was the main histological type in the MLR group (P = 0.023). No significant difference in curative resection rates was observed between the groups. CONCLUSION: The MLR group presented with a greater risk of pathological upgrading after ESD. The findings indicate that ESD is most effective for treating EGC with adjacent MLR after Hp eradication.
Development of an evaluation index system for intelligent minimally invasive tumor ablation based on telemedicine.
Yang W, Zhu B, Li J … +6 more , Wang J, Fan W, Chi C, Zhang Y, Luo F, Liu Z
J Cancer Res Ther · 2025 Sep · PMID 40905878 · Publisher ↗
OBJECTIVE: This study aimed to establish an evaluation index system for intelligent minimally invasive tumor ablation based on telemedicine, thereby providing theoretical support for the assessment, application, and prom...
OBJECTIVE: This study aimed to establish an evaluation index system for intelligent minimally invasive tumor ablation based on telemedicine, thereby providing theoretical support for the assessment, application, and promotion of remote intelligent ablation therapies. METHODS: An expert consultation questionnaire was developed based on a review of the literature. Purposive sampling was performed to select 16 experts specializing in minimally invasive oncology, telemedicine management, and healthcare informatics. Two rounds of Delphi questionnaire surveys were conducted. The index system was finalized through iterative discussions based on expert feedback. The analytical hierarchy process (AHP) was utilized to determine the indicator weights. RESULTS: Both rounds of the questionnaire achieved 100% response rates. The expert authority coefficient reached 0.789, while the Kendall's W coefficients for the two rounds were 0.138 (P < 0.001) and 0.224 (P < 0.001), respectively. The finalized system comprised 6 first-level indicators, 13 second-level indicators, and 45 third-level indicators, establishing a comprehensive management framework for telemedicine-based intelligent tumor ablation. CONCLUSION: The evaluation system established in this study demonstrated scientific validity and reliability. It identified critical success factors for implementing remote ablation procedures, offering a practical reference for advancing telemedicine-enabled minimally invasive cancer therapies.
Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer.
Yi Y, Cao Q, Zhang H … +5 more , Zhang B, Zhang R, Li X, Kong L, Li B
J Cancer Res Ther · 2025 Sep · PMID 40905877 · Publisher ↗
OBJECTIVE: To evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy (NICT) in treating locally advanced resectable esophageal squamous cell carcinoma (ESCC). MATERIALS AND METHODS: This retrospective analysi...
OBJECTIVE: To evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy (NICT) in treating locally advanced resectable esophageal squamous cell carcinoma (ESCC). MATERIALS AND METHODS: This retrospective analysis included 379 patients, who received NICT (PD-1 inhibitors + chemotherapy) before surgery at Shandong Cancer Hospital from January 1, 2020, to January 1, 2025. Pathological responses were assessed using standardized criteria, including pathological complete response (pCR), major pathological response (MPR), and tumor regression grade (TRG). Survival analysis was performed using Kaplan-Meier methods, and multivariate Cox regression models were constructed to evaluate the relationship between NICT and survival outcomes. RESULTS: The pCR, MPR, and significant tumor reduction rates were 27.2%, 41.8%, and 81.6%, respectively. Poor tumor differentiation and early clinical stage were associated with improved treatment responses. Patients achieving pCR, MPR, or TRG0-1 had significantly better overall survival rates compared with other groups (P < 0.0001). NICT demonstrated acceptable toxicity, with anastomotic leakage (9.0%) and pneumonia (17.9%) being the primary complications. CONCLUSION: NICT significantly improves pathological response and survival rates in patients with locally advanced resectable ESCC, with a favorable safety profile. These findings highlight the potential of NICT to transform the treatment landscape of ESCC. Future research should focus on the optimizing treatment regimens, identifying predictive biomarkers, and reducing toxicity to improve clinical outcomes and achieve personalized treatment.
Precision treatment patterns and prognostic analysis: A retrospective study of small-cell lung cancer.
Wang Y, Cheng X, Lin Y … +2 more , Zhang X, Liu Y
J Cancer Res Ther · 2025 Sep · PMID 40905876 · Publisher ↗
INTRODUCTION: In the past decade, the treatment methods for small-cell lung cancer (SCLC) have undergone advances and diversification. This study aimed to explore the treatment patterns of patients with SCLC and evaluate...
INTRODUCTION: In the past decade, the treatment methods for small-cell lung cancer (SCLC) have undergone advances and diversification. This study aimed to explore the treatment patterns of patients with SCLC and evaluate the efficacy of SCLC treatments in a real clinical setting. MATERIALS AND METHODS: This retrospective study included patients with limited-stage (LS) and extensive-stage (ES) SCLC who received treatment at Qingdao Central Hospital (Qingdao, China) from August 1, 2016, to April 30, 2023. The progression-free survival (PFS) and overall survival (OS) were evaluated for all enrolled patients and participant subgroups via Kaplan-Meier survival analysis. RESULTS: A total of 83 and 117 patients with LS-SCLC and ES-SCLC, respectively, were enrolled. The median PFS and OS were 14.5 and 33.4 months for the LS-SCLC group and 9.8 and 20.1 months for the ES-SCLC group, respectively. First-line thoracic consolidative radiotherapy (TRT) and immune checkpoint inhibitors markedly prolonged the PFS in the ES-SCLC group (P = .023 and P = .045, respectively), whereas TRT alone significantly prolonged the OS (P = .036). PFS and OS were significantly prolonged in the LS-SCLC group in whom TRT was initiated during or before the second cycle of first-line chemotherapy (P = .031 and P = .041, respectively). Moreover, patients with at least three areas of lymph node metastasis had significantly poorer prognosis than those with fewer areas. CONCLUSION: The patients in this study exhibited better prognosis than those in previous ones. TRT remains an important treatment that can improve the prognosis of patients with SCLC. However, new strategies are warranted for a more effective treatment.
Pharmacovigilance study of ramucirumab: A safety analysis based on the FDA adverse event reporting system.
Song M, Xie J, Yang L … +1 more , Liu Z
J Cancer Res Ther · 2025 Sep · PMID 40905875 · Publisher ↗
BACKGROUND: This study analyzes adverse event (AE) signals associated with ramucirumab using data from the FDA Adverse Event Reporting System (FAERS) to provide evidence supporting the safety of the drug for clinical use...
BACKGROUND: This study analyzes adverse event (AE) signals associated with ramucirumab using data from the FDA Adverse Event Reporting System (FAERS) to provide evidence supporting the safety of the drug for clinical use. METHODS: Data were extracted from the FAERS database using Open Vigil 2.1. Signal detection was performed using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) methods. AEs were categorized and described using the Preferred Terms (PTs) and System Organ Class (SOC) classifications from the Medical Dictionary for Regulatory Activities. RESULTS: A total of 1,701 AE reports related to ramucirumab were retrieved. Most reported cases involved male patients (59.79%), most aged 65-74 years (25.57%), with Asia being the primary region of report origin (59.08%). Based on the screening criteria, 130 PT signals across 18 SOC categories were identified, of which 72 PTs were not listed in the drug label. Frequently reported and strongly signaled AEs included hypertension, ascites, proteinuria, edema, and neutropenia-events already noted in the prescribing information of the drug. However, additional AEs, such as pyogenic granuloma, brainstem hemorrhage, interstitial lung disease, and peritonitis, which were not included in the labeling, also showed strong signals and warrant further exploration. CONCLUSIONS: The commonly reported AEs of ramucirumab observed in real-world data are consistent with those listed on the drug label. Nevertheless, new suspicious AEs were identified. Enhanced clinical vigilance, through pretreatment risk assessment and ongoing posttreatment monitoring, is recommended to ensure patient safety.
A comparative study of dexmedetomidine combined with esketamine and sufentanil for sedation and analgesia in patients undergoing microwave ablation of lung tumors: A prospective single-center randomized double-blind clinical trial.
Li Y, Li Y, Zhang Y … +6 more , Liu G, Guo J, Zhang Y, Xie Y, Yang N, Chen Y
J Cancer Res Ther · 2025 Sep · PMID 40905874 · Publisher ↗
BACKGROUND: This study evaluated the efficacy and safety of esketamine plus dexmedetomidine for sedation and analgesia during computed tomography (CT)-guided lung tumor percutaneous microwave ablation (MWA). METHODS: Pat...
BACKGROUND: This study evaluated the efficacy and safety of esketamine plus dexmedetomidine for sedation and analgesia during computed tomography (CT)-guided lung tumor percutaneous microwave ablation (MWA). METHODS: Patients undergoing CT-guided percutaneous MWA of lung tumors were randomly divided into two groups: esketamine plus dexmedetomidine (Group E) and sufentanil plus dexmedetomidine (Group S). The patients' general information, mean arterial pressure (MAP), heart rate (HR), peripheral oxygen saturation, respiratory rate (RR), partial pressure of end-tidal carbon dioxide, bispectral index, and Ramsay sedation score were recorded before anesthesia administration (T0), after dexmedetomidine loading dose (T1), during percutaneous puncture (T2), during ablation (T3), at the end of surgery (T4), and during recovery of consciousness (T5). The postoperative Visual Analog Scale (VAS) scores, dexmedetomidine dosage, vasoactive drug usage, instances of sedation failure, and adverse events were also recorded. RESULTS: Group E showed higher MAP at T5 (P = 0.048) and HR at T3 (P = 0.044) compared to Group S. The RR was significantly higher in Group E than in Group S from T1 to T5 (P < 0.001). The incidence of respiratory depression, bradycardia, and postoperative nausea and vomiting in Group E was lower in Group E than in Group S. No significant differences in Ramsay sedation scores, postoperative VAS scores, dexmedetomidine dosage, vasoactive drug usage, number of sedation failure cases, or occurrence of adverse events were observed between the two groups. CONCLUSION: Esketamine plus dexmedetomidine demonstrated potential advantages for lung tumor MWA compared to sufentanil plus dexmedetomidine.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe